XRAY at a glance
DENTSPLY SIRONA Inc (XRAY, SEC CIK 818479) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 7, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), DENTSPLY SIRONA Inc (XRAY) reported revenue of $3.7 billion (down 3.0% from FY2024) and a net loss of $598.0 million. Diluted EPS was -$3.00.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding DENTSPLY SIRONA Inc (XRAY) shares worth $983.0 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by HOSEIN CLYDE on June 15, 2026 of 6,500 shares at $9.98 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.7B
- −3.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 35 funds
- $983.0M · +2 vs prior quarter
- Latest 10-Q
- Aug 6, 2026
- Quarterly report
SignalX for XRAY
Don't miss the next XRAY filing
- Alerts as it files. A push when XRAY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut XRAY, by share count.
- Ask anything. An AI agent that reads every XRAY filing and answers with sources.
XRAY alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MAZELSKY JONATHAN JAY | A | Sep 30, 2026 | 3,323.433 | $9.03 |
| Fortson John C. | A | Aug 10, 2026 | 104,200 | - |
| Fortson John C. | A | Aug 10, 2026 | 24,014 | - |
| Frohning Andrea L. | F | Aug 7, 2026 | 802 | $12.12 |
| MAZELSKY JONATHAN JAY | A | Jun 30, 2026 | 2,841.83 | $10.56 |
| HOSEIN CLYDE | Buy | Jun 15, 2026 | 6,500 | $9.98 |
| Gladden Brian T | Buy | Jun 15, 2026 | 9,985.022 | $10.02 |
| MAZELSKY JONATHAN JAY | A | Jun 12, 2026 | 10,000 | $10.14 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.8B | $3.7B |
| Gross Profit | - | $2.0B | $1.8B |
| Operating Income | - | -$879.0M | -$422.0M |
| Net Income | - | -$910.0M | -$598.0M |
| Gross Margin | - | 51.6% | 50.0% |
| Op. Margin | - | -23.2% | -11.5% |
| Net Margin | - | -24.0% | -16.3% |
| Balance Sheet | |||
| Total Assets | $7.4B | $5.8B | $5.4B |
| Equity | $3.3B | $1.9B | $1.3B |
| ROE | - | -46.9% | -44.7% |
| Per Share | |||
| EPS | $-0.62 | $-4.48 | $-3.00 |
| Cash Flow | |||
| Operating CF | $377.0M | $461.0M | $235.0M |
Source: XBRL data in DENTSPLY SIRONA Inc (XRAY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate XRAY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $983.0M |
| Q1 2026 | 33 | $839.6M |
| Q4 2025 | 31 | $898.6M |
| Q3 2025 | 32 | $1.14B |
| Q2 2025 | 32 | $1.58B |
| Q1 2025 | 28 | $933.2M |
| Q4 2024 | 26 | $946.8M |
| Q3 2024 | 24 | $686.9M |
- BlackRock+7.46M (+39%)
- AQR Capital Management+6.49M (+164%)
- State Street Corp+2.04M (+28%)
- Vanguard Portfolio Management LLC+1.25M (+12%)
- Goldman Sachs Group+1.18M (+179%)
- Renaissance Technologies LLC−1.54M (-98%)
- Citadel Advisors LLC−631.1K (-45%)
- Morgan Stanley−413.4K (-17%)
- Dimensional Fund Advisors−98.8K (-3%)
- Raymond James Financial−50.9K (-9%)
- Bridgewater Associates LP+370.0K
- Allstate+78.0K
- Citizens Financial Group+11.1K
- M&T Bank−20.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
XRAY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
XRAY SEC filings: frequently asked questions
Which institutions hold XRAY stock?
As of June 30, 2026, the largest DENTSPLY SIRONA Inc (XRAY) holders among the 13F filers tracked by SignalX were BlackRock ($283.4 million), Vanguard Portfolio Management LLC ($125.0 million), AQR Capital Management ($110.2 million), State Street Corp ($98.5 million), Vanguard Capital Management LLC ($96.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was XRAY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), DENTSPLY SIRONA Inc (XRAY) reported revenue of $3.7 billion (down 3.0% from FY2024) and a net loss of $598.0 million. Diluted EPS was -$3.00. The figures come from the XBRL data in the 10-K.
What are the latest XRAY SEC filings?
DENTSPLY SIRONA Inc (XRAY) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 7, 2026 and a Form 4 insider filing on October 2, 2026.
What is XRAY's SEC CIK number?
DENTSPLY SIRONA Inc (XRAY)'s SEC Central Index Key (CIK) is 818479. EDGAR lists every XRAY filing under that number.
Ask anything about XRAY
The research agent reads XRAY's filings, financials, insider trades and 13F holders, then answers with sources.